Literature DB >> 11000458

Vaccine potential of poly-1-6 beta-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis.

D Mckenney1, K Pouliot, Y Wang, V Murthy, M Ulrich, G Döring, J C Lee, D A Goldmann, G B Pier.   

Abstract

Staphylococcus aureus and S. epidermidis are among the most common causes of nosocomial infection, and S. aureus is also of major concern to human health due to its occurrence in community-acquired infections. These staphylococcal species are also major pathogens for domesticated animals. We have previously identified poly-N-succinyl beta-1-6 glucosamine (PNSG) as the chemical form of the S. epidermidis capsular polysaccharide/adhesin (PS/A) which mediates adherence of coagulase-negative staphylococci (CoNS) to biomaterials, serves as the capsule for strains of CoNS that express PS/A, and is a target for protective antibodies. We have recently found that PNSG is made by S. aureus as well, where it is an environmentally regulated, in vivo-expressed surface polysaccharide and similarly serves as a target for protective immunity. Only a minority of fresh human clinical isolates of S. aureus elaborate PNSG in vitro but most could be induced to do so under specific in vitro growth conditions. However, by immunofluorescence microscopy, S. aureus cells in infected human sputa and lung elaborated PNSG. The ica genes, previously shown to encode proteins in CoNS that synthesize PNSG, were found by PCR in all S. aureus strains examined, and immunogenic and protective PNSG could be isolated from S. aureus. Active and passive immunization of mice with PNSG protected them against metastatic kidney infections after intravenous inoculation with eight phenotypically PNSG-negative S. aureus. Isolates recovered from kidneys expressed PNSG, but expression was lost with in vitro culture. Strong antibody responses to PNSG were elicited in S. aureus infected mice, and a PNSG-capsule was observed by electron microscopy on isolates directly plated from infected kidneys. PNSG represents a previously unidentified surface polysaccharide of S. aureus that is elaborated during human and animal infection and is a prominent target for protective antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000458     DOI: 10.1016/s0168-1656(00)00296-0

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  13 in total

1.  icaR encodes a transcriptional repressor involved in environmental regulation of ica operon expression and biofilm formation in Staphylococcus epidermidis.

Authors:  Kevin M Conlon; Hilary Humphreys; James P O'Gara
Journal:  J Bacteriol       Date:  2002-08       Impact factor: 3.490

Review 2.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 3.  Skin microbiota: a source of disease or defence?

Authors:  A L Cogen; V Nizet; R L Gallo
Journal:  Br J Dermatol       Date:  2008-03       Impact factor: 9.302

4.  Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment.

Authors:  Rebecca A Brady; Graeme A O'May; Jeff G Leid; Megan L Prior; J William Costerton; Mark E Shirtliff
Journal:  Infect Immun       Date:  2011-01-10       Impact factor: 3.441

5.  Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection.

Authors:  Andrea Kropec; Tomas Maira-Litran; Kimberly K Jefferson; Martha Grout; Sarah E Cramton; Friedrich Götz; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Extracellular carbohydrate-containing polymers of a model biofilm-producing strain, Staphylococcus epidermidis RP62A.

Authors:  Irina Sadovskaya; Evgueny Vinogradov; Sigrid Flahaut; Grigorij Kogan; Saïd Jabbouri
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 7.  [Postoperative and bacterial osteitis. New possibilities for therapy].

Authors:  V Heppert; U Glatzel; A Wentzensen
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

8.  Real-time monitoring of bacterial infection in vivo: development of bioluminescent staphylococcal foreign-body and deep-thigh-wound mouse infection models.

Authors:  Nelly A Kuklin; Gregory D Pancari; Timothy W Tobery; Leslie Cope; Jesse Jackson; Charles Gill; Karen Overbye; Kevin P Francis; Jun Yu; Donna Montgomery; Annaliesa S Anderson; William McClements; Kathrin U Jansen
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Inactivations of rsbU and sarA by IS256 represent novel mechanisms of biofilm phenotypic variation in Staphylococcus epidermidis.

Authors:  Kevin M Conlon; Hilary Humphreys; James P O'Gara
Journal:  J Bacteriol       Date:  2004-09       Impact factor: 3.490

10.  Inhibition of Staphylococcus epidermidis biofilm formation by rabbit polyclonal antibodies against the SesC protein.

Authors:  Mohammad Shahrooei; Vishal Hira; Benoit Stijlemans; Rita Merckx; Peter W M Hermans; Johan Van Eldere
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.